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Purpose: Ocular neovascularization is a leading cause of blindness in ischemic retinopathies. Hypericin is an active
ingredient in the medical herb St. John’s Wort (SJW). Because hypericin inhibits intracellular signaling pathways that are
believed to participate in the regulation of angiogenesis, we investigated the actions of hypericin and SJW in retinal
neovascularization, using a mouse model of oxygen-induced retinopathy (OIR).
Methods: C57BL/6 neonatal mice were exposed to a 75% concentration of oxygen from postnatal day 7 (P7) to P12 and
returned to room air from P12 to P17 to induce retinal neovascularization. SJW (15 mg/kg/day), hypericin (15, 45, or 135
μg/kg/day), or vehicle was given by gavage once a day for five days from P12 to P17. To quantify the area of retinal
neovascularization and vasoobliteration, we stained retinas with isolectin B4 at P17. Phosphorylation of extracellular
signal-regulated  kinase  (ERK)  in  ischemic  retinas  was  determined  by  western  blot  analysis.  To  estimate  retinal
vascularization, we stained retinas with isolectin B4 at P7 after treatment with SJW, hypericin, or vehicle from P3 to P7.
Results: Gavage administration of hypericin or SJW significantly inhibited the degree of retinal neovascularization, but
did not affect the area of retinal vasoobliteration in a mouse model of OIR. Both SJW and hypericin had no effect on
normal vascularization over the treatment time course. Treatment with SJW or hypericin reduced phosphorylation of ERK
in the retina.
Conclusions:  These  data  suggest  that  hypericin  and  SJW  reduce  pathological  retinal  neovascularization  and  that
administration of these agents could have clinical utility for treatment of ischemic retinopathies.
New blood vessel formation is an essential feature in the
development  of  several  pathological  conditions  including
tumor  growth,  proliferative  retinopathies,  psoriasis,
rheumatoid arthritis, osteoarthritis, and atherosclerosis [1].
Ocular  neovascularization  causes  vision  loss  in  various
ischemic  retinal  disorders  including  retinopathy  of
prematurity and diabetic retinopathy [2,3]. Several angiogenic
growth  factors  and  cytokines  that  stimulate  angiogenesis
participate in the pathogenesis of retinal neovascularization
[4-6].  Among  them,  vascular  endothelial  growth  factor
(VEGF), a potent endothelial cell-specific mitogen, plays a
key role in regulation of new blood vessel growth in retina
during pathological conditions [2,5].
VEGF binds to its receptors and stimulates a variety of
signaling  molecules,  resulting  in  promotion  of
neovascularization [7-10]. Both extracellular signal-regulated
kinase (ERK) and protein kinase C (PKC) are activated by
VEGF  and  contribute  to  the  induction  of  endothelial  cell
proliferation and migration, which are essential for regulation
of angiogenesis [9,11-13]. Inhibition of PKC by tranilast, an
antiallergic  compound  is  associated  with  reduction  of
angiogenic  activities  in  retinal  microcapillary  endothelial
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cells [12]. Intravitreous injection of ERK inhibitors leads to
suppression of retinal neovascularization in a rat model of
retinopathy of prematurity [14]. Therefore, therapies aimed at
inhibiting  VEGF-mediated  signaling  pathways  may  have
efficacy  in  the  treatment  of  pathological  retinal
neovascularization [6,15].
Hypericum perforatum, also known as St. John’s Wort
(SJW), is a popular herbal supplement that is believed to exert
antidepressant  effects  [16,17].  SJW  also  displays  various
pharmacological  activities  including  antiviral  and
antineoplastic properties [16,17]. SJW contains various active
constituents  such  as  hypericin,  hyperforin,  tannins,  and
flavonoids [16,17]. Hypericin is a photodynamic compound
that is one of the major active components of SJW. Hypericin
has been shown to suppress several phosphorylation signaling
pathways, including ERK and PKC in cultured cells [18,19].
These reports led us to hypothesize that SJW and its active
component  hypericin  could  negatively  regulate  ischemia-
induced angiogenesis. However, the impact of hypericin or
SJW  on  retinal  neovascularization  in  vivo  has  not  been
examined previously. Thus, we investigated whether SJW or
hypericin  could  modulate  retinal  neovascularization  in  a
mouse model of ischemic retinopathy.
METHODS
A mouse model of oxygen-induced retinopathy: All animal
experiments  were  performed  in  accordance  with  the
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249Statement for the Use of Animals in Ophthalmic and Vision
Research.  The  Committee  of  Animal  Use  of  the  Kansai
Medical  University  approved  the  experimental  protocol.
(Adult male mice; n=15, adult female mice; n=30) C57BL/6
mice  were  obtained  from  CLEA  Japan  (Tokyo,  Japan).
Neonatal mice were subjected to oxygen-induced
retinopathy  as  described  previously  [20].  Briefly
postnatal day 7 (P7) mice with their nursing mothers were
exposed to 75%±2% oxygen (hyperoxia) for five days (P7–
12) to produce retinal vasoobliteration, and returned to room
air (normoxia) for five days (P12–17) to induce ischemic
retinal neovascularization.
At P12, after pups were exposed to 75% oxygen, they
were  categorized  into  three  groups:  SJW  (15  mg/kg/day,
which is the approximately same dose used as a supplement
for  humans),  hypericin  (15,  45,  and  135  µg/kg/day),  and
vehicle group. Hypericin purified from SJW was purchased
from  Alexis  Biochemicals  (Lausen,  Switzerland).  SJW
formulations are standardized to include 0.3% concentration
of total hypericin containing hypericin and pseudohypericin,
and the amount of pseudohypericin in SJW is around two to
four times higher than that of hypericin [17,21]. Thus, the
concentration of hypericin found in SJW appears to range
between 0.06 and 0.1%. The amount of hypericin (15 µg/kg/
day) approximately corresponds to that present in the dose of
SJW (15 mg/kg/day). SJW and hypericin were dissolved in
dimethyl sulfoxide (DMSO) and diluted with water to adjust
the final concentration of DMSO to 0.5%. Vehicle contained
0.5% concentration of DMSO. SJW, hypericin, or vehicle was
placed in the stomach by gavage once a day for five days. At
P17 after five days of gavage treatment, mice were sacrificed
by intraperitoneal injection with an overdose of ketamine (300
mg/kg) and xylazine (30 mg/kg).
Quantification  of  retinal  vasoobliteration  and
neovascularization: Eyes were removed from mice at P17 and
fixed in 4% paraformaldehyde for 1 h at 4 °C. The retinas were
dissected. They were then stained with Griffonia Simplicifolia
Isolectin B4 conjugated with Alexa Fluor 594 (Molecular
Probes, Carlsbad, CA) for 16 h at 4 °C to detect vascular
endothelial  cells  [22].  The  retinas  were  washed  with
phosphate-buffered saline (PBS) for 2 h. Four radical cuts
were made from the edge of each retina to the center, dividing
the  retina  into  four  quadrants,  before  it  was  mounted  in
mounting  media  (Vector  Laboratories,  Burlingame,  CA).
Pictures  of  whole-mounts  of  retinas  were  taken  at  5X
magnification by fluorescence microscopy. Retinal segments
were  merged  to  generate  a  whole  retinal  image  using
Adobe®  Photoshop®  Version  7.0  (San  Jose,  CA).
Vasoobliteration  and  neovascular  tuft  formation  were
quantified by comparing the number of pixels in the affected
areas with the total number of pixels in the retina. Investigators
were blinded to the mouse treatment.
Quantification  of  retinal  vascular  development:  SJW,
hypericin, or vehicle was administered to mice by gavage once
a day from P3 to P7. At P7, eyes were enucleated and fixed
with 4% paraformaldehyde for 1 h at 4 °C. The retinas were
washed with PBS then dissected and incubated for 16 h at 4 °C
with biotinylated Griffonia Simplicifolia isolectin B4 (Vector
Laboratories, Burlingame, CA) diluted in PBS containing 1%
Triton X-100 (Sigma-Aldrich, St. Louis, MO). Retinas were
washed with PBS followed by incubation with fluorescein-
isothiocyanate-streptavidin (Dako Corp., Glostrup, Denmark)
for 16 h at 4 °C. Radial cuts were made in the peripheral retina
Figure 1. St. John’s Wort and hypericin inhibit ischemia-induced retinal vessel formations. Shown are representative photographs of retinas
stained with isolectin B4. Mice at P7 were reared in 75% oxygen for five days followed by room air for five days. St. John’s Wort (B) (SJW;
15 mg/kg/day), hypericin (C) (45 µg/kg/day), and vehicle (A) were administered to mice by gavage from P12 to p17. Retinas were isolated
and stained with isolectin B4 to detect vasoobliteration and neovascularization. Magnification is X 5.
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250to  allow  whole  mounting  in  mounting  medium  (Vector
Laboratories). The whole-mounted retinas were analyzed by
fluorescence microscopy. Vasculature length was measured
from the optic disc to the edge of the vascular front in all four
retinal  quadrants  using  Image-Pro  Plus  software  (Media
Cybernetics, Silver Springs, MD) [6], and the average value
was taken for each retina.
Western blot analysis: Retinas were collected at P17 after
treatment with SJW, hypericin, or vehicle for five days (P12-
P17). Retinas were homogenized and sonicated in lysis buffer
(Cell  Signaling,  Danvers,  MA)  with  protease  inhibitors
(Sigma).  Protein  concentrations  were  measured  using  the
BCA protein assay kit (Pierce, Rockford, IL), and the same
amounts  of  retinal  lysates  were  resolved  by  SDS–PAGE.
Phospho-p42/44 ERK (Thr 202/Tyr 204) and ERK antibodies
were purchased from Cell Signaling. β-actin antibody was
purchased from Sigma. The membranes were immunoblotted
with  the  indicated  first  antibodies  at  a  1:1000  dilution
followed  by  the  second  antibodies  conjugated  with
horseradish peroxidase at a 1:5000 dilution. Retinas were
isolated from four mice per group. The same experiments
were repeated three times.
Statistical analysis: All values are presented as mean ± SEM.
ANOVA was used to determine the differences among more
than  three  groups.  A  level  of  p<0.05  was  accepted  as
statistically significant.
RESULTS
St.  John’s  Wort  and  hypericin  inhibit  retinal
neovascularization in mice with ischemic retinopathy: First,
we investigated the impact of SJW (15 mg/kg/day) which
approximately corresponds to the dose used as a supplement
for humans, on ischemia-mediated retinal neovascularization
in a mouse model of OIR. Representative photographs of
isolectin B4-stained retinal vasculature in P17 mice are shown
in Figure 1. Vehicle-treated mice exhibited a marked increase
in  multiple  neovascular  tufts,  showing  neovascularization
throughout the retina (Figure 1A). In contrast, SJW-treated
mice  showed  an  apparent  decrease  in  neovascularization
compared with vehicle-treated mice (Figure 1B). Quantitative
analyses revealed that oral SJW administration significantly
reduced the area of neovascularization in retinas compared
with vehicle (Figure 2A). The vasoobliteration area did not
differ between the two groups (Figure 2B).
Because hypericin is one of major bioactive constituents
of  SJW,  we  also  examined  its  effect  on  retinal
neovascularization. Mice were treated with different doses of
hypericin (15, 45, and 135 µg/kg/day). Hypericin treatment
significantly inhibited the degree of retinal neovascularization
in a dose-dependent fashion (Figure 1C, 2A). Treatment with
hypericin at the dose of 15 µg/kg/day inhibited the retinal
neovascularization to levels that were similar to that observed
in SJW-treated mice (Figure 2A). The vasoobliteration area
did not differ between hypericin-treated and vehicle-treated
mice (Figure 2B).
Retinal vascularization is not affected by treatment with St.
John’s Wort and hypericin: Next, we tested whether SJW and
hypericin  influence  physiologic  retinal  vessel  growth  as
determined by staining with isolectin B4 at P7. Representative
photographs of lectin-stained vessels in the retina of P7 mice
are  shown  in  Figure  3  A-C.  Quantitative  analysis  was
Figure  2.  St.  John’s  Wort  and  hypericin  inhibit  retinal
neovascularization.  Quantification  of  neovascularization  (A)  and
vasoobliteration  (B)  was  performed  after  gavage  treatment  with
either 15 mg/kg/day St. John’s Wort (SJW; n=18), 15 µg/kg/day
hypericin (n=12), 45 µg/kg/day hypericin (n=18), 135 µg/kg/day
hypericin  (n=12),  or  vehicle  (n=24).  The  percentages  of  retinal
neovascularization  and  vasoobliteration  were  quantified  by
comparing the number of pixels in the affected areas with the total
number of pixels in the retina. Data are presented as mean ± SEM.
Asterisk  (*)  indicates  p<0.01  versus  vehicle  treatment.  Double
asterisk  (**)  denotes  p<0.05  versus  hypericin  (15  µg/kg/day)
treatment. N.S. means the data was not statistically significant.
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251performed by measurement of the length from optic disc to
the edge of retinal vessels. Both SJW and hypericin treatment
had no effect on the length of vessels under these conditions
(Figure 3D).
St. John’s Wort and hypericin reduce extracellular signal-
regulated kinase phosphorylation in retinas: Because ERK
plays important roles in the angiogenic responses, including
retinal  neovascularization  [14,23],  we  used  western  blot
analysis to assess the phosphorylation of ERK at Thr-202/
Tyr-204 in retinas in each experimental group. SJW treatment
markedly suppressed ERK phosphorylation in ischemic retina
compared  with  vehicle  (Figure  4).  Similarly,  ERK
phosphorylation was diminished by treatment with hypericin
(Figure 4). Both SJW and hypericin treatment had no effect
on total ERK protein levels.
DISCUSSION
Our data provide in vivo evidence that SJW and its active
ingredient, hypericin, inhibit the development of ischemic
retinal  neovascularization  in  a  mouse  model  of  ischemic
retinopathy  without  affecting  physiologic  vascularization.
Figure 3. Effect of St. John’s Wort and hypericin on physiologic
vascularization in the retina. A-C: Shown are representative images
of mouse retinas immunostained with isolectin B4 after treatment
with 15 mg/kg/day St. John’s Wort (SJW; n=18), 45 µg/kg/day
hypericin (n=16), or vehicle (n=18) from P3 to P7. Magnification is
X 5. D: Measurement of length of vasculature from the optic disc to
the edge of the vascular front. Data are presented as mean ± SEM.
N.S. means the data was not statistically significant.
Furthermore, the effects correlated with the ability of both
SJW and hypericin to inhibit ERK phosphorylation under
ischemic conditions. These data suggest that both SJW and
hypericin  could  attenuate  pathological  retinal
neovascularization  through  its  ability  to  suppress  ERK
activation.
It  has  been  shown  that  hypericin  suppresses  several
angiogenic responses of bovine endothelial cells including
endothelial  growth,  migration,  and  differentiation  into
vascular-like  structure  [24].  Hypericin  also  reduces
proliferation and tube formation in choroidal endothelial cells
[25]. Hypericin is reported to inhibit fibroblast growth factor
Figure 4. St. John’s Wort and hypericin inhibit extracellular signal-
regulated kinase activation in retina. Retinas were harvested from
eyes of mice following gavage administration of vehicle, 15 mg/kg/
day St. John’s Wort (SJW) or 45 µg/kg/day hypericin from P12
through P17. Levels of phosphorylated ERK (P-ERK), total ERK,
and actin were determined by western blot analysis. Representative
blots from three experiments are shown. Phosphorylation levels of
ERK were quantified by NIH image analysis. Immunoblots were
normalized to total loaded protein. Data are presented as mean ±
SEM. Asterisk (*) indicates p<0.01 versus vehicle treatment.
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252-2-induced angiogenesis in a rat corneal assay in vivo [26].
Consistent with the antiangiogenic effects of hypericin under
nonischemic  conditions,  the  present  study  indicates  that
ischemia-induced  retinal  neovascularization  is  effectively
diminished after treatment with hypericin. Collectively, these
data suggest that hypericin can act as a general repressor of
angiogenesis under pathological conditions.
In  the  present  study,  a  therapeutic  dose  of  SJW
significantly  attenuated  retinal  neovascularization  in  vivo.
Hypericin also inhibited retinal neovascularization in a dose-
dependent manner. Hypericin at the lowest dose was equally
or less effective at inhibiting retinal neovascularization than
SJW.  Because  this  dose  of  hypericin  was  approximately
proportional to that present in the dose of SJW, hypericin may
partly account for the antiangiogenic actions of SJW. SJW
also includes another active constituent, hyperforin, which is
reported to mimic the antidepressive effects of SJW [17]. It
has been reported that hyperforin inhibits vessel growth in
vivo determined by chorioallantoic membrane assay, and that
it  also  suppresses  angiogenic  responses  including
proliferation  and  tube-like  structure  formation  in  cultured
endothelial  cells  [27].  In  addition,  SJW  contains  several
flavonoids, such as rutin and quercetin. These flavonoids may
also inhibit angiogenesis in vivo and in vitro [28,29]. Thus,
SJW has several active components showing antiangiogenic
properties.
VEGF  is  critical  for  the  determination  of
neovascularization  in  ischemic  ocular  diseases,  including
diabetic  retinopathy  [2,5,15],  and  inhibition  of  VEGF
signaling results in reduction of retinal angiogenesis [6,14,
15,30,31].  VEGF  stimulation  leads  to  ERK  activation  in
endothelial  cells  [7-9].  In  this  regard,  hypericin  has  been
shown  to  suppress  ERK  activation  in  both  cancer  and
endothelial cell lines [18,26]. In line with these observations,
our  data  show  that  hypericin  suppressed  ERK
phosphorylation in a mouse model of OIR. Therefore, the
inhibitory actions of hypericin on neovascularization may be
mediated partly by its ability to suppress VEGF-stimulated
signaling.
In  summary,  we  show  that  both  hypericin  and  SJW
protect against pathological retinal neovascularization in mice
with ischemic retinopathy. The beneficial effects of SJW and
hypericin  are  associated  with  reduced  ERK  activation  in
retina.  Thus,  these  agents  could  be  potentially  useful  for
treatment of ischemic ocular diseases.
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